Skip to main content
Premium Trial:

Request an Annual Quote

Bayer, Broad Expand Collaboration to Include Cardiovascular Genomics

NEW YORK (GenomeWeb) – Bayer HealthCare today announced it has expanded a drug development collaboration with the Broad Institute to include cardiovascular genomics. 

As part of the expanded deal, Bayer and the Broad will collaborate on genetic discovery, target identification, and drug discovery activities. A joint steering committee and joint research committee will oversee research progress and direction, Bayer said. Financial and other terms of the deal were not disclosed. 

The deal expands an agreement reached by the partners in September 2013 to discover and develop therapeutic agents targeting cancer genome alterations.

Bayer said that while lifestyle factors, such as smoking, diet, and exercise, are the main culprits behind heart disease, genetic factors can influence the predisposition to cardiovascular disease, the age of onset, and severity.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.